A real-world study reported that Nefecon—targeted-release budesonide—reduced proteinuria and helped preserve kidney function in patients with primary IgA nephropathy, including those starting with relatively lower proteinuria levels. The findings provide practical evidence for how Nefecon performs outside randomized trial settings. Real-world outcomes are increasingly used to guide payer discussions and clinician selection, especially where label populations include a broad range of baseline disease characteristics. The study adds to ongoing efforts to clarify which patient subsets derive the most measurable kidney-protective benefit from targeted-release steroid therapy.